Article from Parkinson's News Today earlier this month on our Kannalife Sciences, Inc. $1.49M grant award from The Michael J. Fox Foundation for Parkinson's Research This grant will support the development of our lead therapeutic, #KLS13019, addressing neuroinflammation and mitochondrial dysfunction—two key factors in Parkinson’s disease. #ParkinsonsResearch #Biotech #Research #Innovation #neuroiflammation #mitochondria #mitochondrialdysfunction #GPCR #GPR55 #NCX1 #mNCX1 #NLRP3 #CannabinoidTherapeutics #Neurodegeneration #Neuropathix Neuropathix, Inc. #Kannalife #MJFF https://lnkd.in/gpXfX5xy
Kannalife Sciences, Inc.
Pharmaceutical Manufacturing
Doylestown, PA 489 followers
a subsidiary of Neuropathix, Inc. (OTCQB: NPTX)
About us
Kannalife Sciences, Inc. (“Kannalife”), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by TIME Magazine/SI as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy et al.”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, to treat Hepatic Encephalopathy (“HE”), Chronic Traumatic Encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy ("CIPN"). <iframe width="560" height="315" src="https://www.youtube.com/embed/LWLbe9m4JWo" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe>
- Website
-
http://www.neuropathix.com
External link for Kannalife Sciences, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Doylestown, PA
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Biotechnology, Pharmaceuticals, Cannabinoids, Phyto-Medical, Hepatic Encephalopathy, Chronic Traumatic Encephalopathy, Chemotherapy Induced Peripheral Neuropathy, HE, CTE, CIPN, Cannabidiol, KLS-13019, US Patent #6630507, and US Patent #9611213
Locations
-
Primary
Get directions
3805 Old Easton Road
Doylestown, PA 18902, US
Employees at Kannalife Sciences, Inc.
Updates
-
We are thrilled to share that Kannalife Sciences, Inc. has secured $1.49 million in funding from The Michael J. Fox Foundation for Parkinson's Research. This grant will support the development of our lead therapeutic, KLS-13019, addressing neuroinflammation and mitochondrial dysfunction—a key factor in Parkinson’s disease. Our heartfelt thanks to The Michael J. Fox Foundation, our dedicated team, and research partners. Together, we are advancing the frontier of neurodegenerative disease treatment. #ParkinsonsResearch #Biotech #Research #Innovation #CannabinoidTherapeutics #Neurodegeneration #Kannalife #MJFF https://lnkd.in/gC4qmGdK
Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research
globenewswire.com
-
Reminder our CEO Dean Petkanas is presenting at the BIO International Convention on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am
CEO Dean Petkanas is presenting at the BIO International Convention on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am
This content isn’t available here
Access this content and more in the LinkedIn app
-
CEO Dean Petkanas is presenting at the BIO International Convention on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am
This content isn’t available here
Access this content and more in the LinkedIn app
-
We're excited and honored to announce that Kannalife Sciences, Inc. has been selected by the The National Institutes of Health (NIH) as one of the 30 NIH SEED Companies to have earned the privilege to present at the BIO International Convention in San Diego. Save the Date: Our CEO Dean Petkanas is presenting on Tuesday, June 4, 2024 at 4:30pm in Company Presentation Theater 3. Join us also at the NIH booth #825 Tuesday, June 4, 2024 at 11:56 am for a closer look. Thank you to the NIH for the recognition of our team’s commitment and tireless efforts in researching treatments for diseases with unmet medical needs. #bio #bio2024 #NIH #NINDS #pharma #biotech #biotechnology #kannalife #neuropathix #research https://lnkd.in/eVvqkZnh
Dean Petkanas
convention.bio.org
-
At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix, Inc. and Kannalife Sciences, Inc. featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support. #BioNJ #LifeSciences #Biotech #Pharma #Innovation #Networking
At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix, Inc. featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support. #BioNJ #LifeSciences #Biotech #Pharma #Innovation #Networking https://lnkd.in/ewihdEfv
At BioPartnering event, it’s easy to find cheerleaders for (and critics of) state | ROI-NJ
https://www.roi-nj.com
-
🔬 New Research Alert! Kannalife Sciences, Inc. Scientists uncover a link between KLS-13019 and the GPR55 receptor, shedding light on its promising role in reducing inflammatory markers associated with chemotherapy-induced peripheral neuropathy (CIPN). In contrast, cannabidiol (CBD) shows low efficacy, highlighting significant differences between the two compounds. Our recent study in the Journal of Molecular Neuroscience investigates the anti-inflammatory actions of KLS-13019 and CBD in CIPN. 💡 Insights from this study pave the way for targeted therapies and innovative approaches to treating inflammation. Stay tuned. 📚 Read the full study here: https://rdcu.be/dFqru Neuropathix, Inc. #Research #Cannabinoids #PeripheralNeuropathy #NeuroPain #Innovation #HealthScience #Neuroscience #MedicalResearch #Inflammation #GPCR #GPR55 #CIPN #Mitochondria
Knockdown siRNA Targeting GPR55 Reveals Significant Differences Between the Anti-inflammatory Actions of KLS-13019 and Cannabidiol - Journal of Molecular Neuroscience
link.springer.com
-
Dean Petkanas CEO of Neuropathix, Inc. and Kannalife Sciences, Inc. presenting “KLS-13019 - A Remarkable Non-Opioid Drug Discovery for the Treatment of Neuro Pain” on Tune in on April 2, 2024 @ 11:30am EST / 8:30am PST https://lnkd.in/guAsZkYi
1) Recruitment: BioTech & Medical Device 2) Training: Diversity & Inclusion - darshanavnadkarni.wordpress.com
All invited to join tomorrow April 2 at 8:30 am PST talk on zoom - "KLS-13019 - A Remarkable Non-Opioid Drug Discovery for the Treatment of Neuro Pain" by Dean Petkanas, CEO at Kannalife, Inc. - see link in comments. With Harry Wachob RONALD SCHOENGOLD, RAC, FRAPS Patrick Lee Stan Levy
-
Many thanks to the dedicated professionals at the NIH and the Life Sciences Summit for giving us this opportunity to share our groundbreaking technology.
Neuropathix, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a patented product platform of novel molecules from our proprietary socially responsible pain management therapeutics to treat patients with various unmet medical needs. Learn more here: https://neuropathix.com/ #SBIR #STTR
-
-
Please join Neuropathix, Inc. subsidiary Kannalife Sciences, Inc. on October 11, 2023 at the NIH Life Sciences Summit at the Alexandria Life Sciences Center in NYC We're proud to be only one of fifteen innovative, fundable, early-stage life sciences companies selected by NIH to present our breakthrough technology to treat neuropathic pain, inflammation and addiction. #Kannalife #Neuropathix #LifeSciSummit #Biotech #Innovation #InvestmentOpportunity #NYC #EmergingCompanies #EarlyStageInvesting #ScienceLeadership #NIHSummit2023 #HealthcareInnovation #PitchDoctors #StrategicPartners #InvestorsUnite https://lnkd.in/djp--HfM
Emerging Company Showcase
https://lifesciencessummit.org